If you have been reading about REV-ERB and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-18. Numbers and descriptions here follow the published literature rather than marketing material.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
While a broad interpretation of this definition could be used to describe nearly any compound depending on concentration, in practice, it usually refers to compounds that act at the molecular level on translational machinery (either the ribosome itself or the translation factor), taking advantages of the major differences between prokaryotic and eukaryotic ribosome structures.
== Further reading == Bradford, M.M. (1976), "Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding", Anal. Biochem., 72 (1–2): 248–254, doi:10.1016/0003-2697(76)90527-3, PMID 942051, S2CID 4359292 Zor, T.; Selinger, Z. (1996), "Linearization of the Bradford protein assay increases its sensitivity: theoretical and experimental studies", Anal. Biochem., 236 (2): 302–308, doi:10.1006/abio.1996.0171, PMID 8660509 Noble, James E.; Bailey, Marc J.A. (2009). "Chapter 8 Quantitation of Protein". Guide to Protein Purification, 2nd Edition. Methods in Enzymology. Vol. 463. pp. 73–95. doi:10.1016/S0076-6879(09)63008-1. ISBN 978-0-12-374536-1. PMID 19892168. Albright, Brian (2009), Mathematical Modeling with Excel, Jones & Bartlett Learning, p. 60, ISBN 978-0-7637-6566-8 Stephenson, Frank Harold (2003), Calculations for molecular biology and biotechnology: a guide to mathematics in the laboratory, Academic Press, pp. 252, ISBN 978-0-12-665751-7 Dennison, C. (2013). A Guide to Protein Isolation. Springer Science & Business Media. p. 39. ISBN 978-94-017-0269-0. Ibanez, Jorge G. (2007), Environmental chemistry: fundamentals, Springer, p. 60, ISBN 978-0-387-26061-7
== Non-human infections == Streptococcus agalactiae was historically studied as a disease of cattle that harmed milk production, leading to its name "agalactiae" which means "absence of milk". Strains of bovine and human bacteria are generally interchangeable, with evidence of transmission from animals to humans and vice versa.
Sources: en.wikipedia.org
In 2005–06, fragrance mix was the third-most-prevalent allergen in USA patch tests (11.5%). 'Fragrance' was voted Allergen of the Year in 2007 by the American Contact Dermatitis Society. An academic study in the United States published in 2016 has shown that "34.7 % of the population reported health problems, such as migraine headaches and respiratory difficulties, when exposed to fragranced products". The composition of fragrances is usually not disclosed in the label of the products, hiding the actual chemicals of the formula, which raises concerns among some consumers. In the United States, this is because the law regulating cosmetics protects trade secrets. In the United States, fragrances are regulated by the Food and Drug Administration if present in cosmetics or drugs, by the Consumer Product Safety Commission if present in consumer products. No pre-market approval is required, except for drugs. Fragrances are also generally regulated by the Toxic Substances Control Act of 1976 that "grandfathered" existing chemicals without further review or testing and put the burden of proof that a new substance is not safe on the EPA. The EPA, however, does not conduct independent safety testing but relies on data provided by the manufacturer. A 2019 study of the top-selling skin moisturizers found 45% of those marketed as "fragrance-free" contained fragrance. Cosmetics are regulated in the United Kingdom and the composition of products must be provided.
== Production process == Stock cubes are made by mixing already-dry ingredients into a paste, including salt, fat, (meat/bone/vegetable) extract, etc. The ingredients are usually mixed in a container (batch mixing), left to mature, and then shaped into the cube form. Alternatively, they can be mixed directly into an extruder. The "extract" portion needs to be separately produced from the meat, bone, or whatever food is intended to be used in the reconstituted boullion (see meat extract). This is achieved by large-scale cooking similar to what is used to make pre-packaged broth, followed by an evaporation process to condense the product.
However, for such applications actinides are less suitable than lighter radioisotopes as the critical mass is orders of magnitude below the mass needed to produce such amounts of power. As Sr-90, Cs-137 and other lighter radionuclides cannot maintain a nuclear chain reaction under any circumstances, RTGs of arbitrary size and power could be assembled from them if enough material can be produced. In general, however, potential applications for such large-scale RTGs are more the domain of small modular reactors, microreactors or non-nuclear power sources.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.